PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing

Trial Profile

PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms PEAX
  • Most Recent Events

    • 02 Mar 2017 Planned number of patients changed from 67 to 55.
    • 02 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 20 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top